Navigation Links
An Aid to Tailoring Prostate Cancer Treatment
Date:5/16/2009

Study identifies factors to help decide how aggressive therapy should be

FRIDAY, May 15 (HealthDay News) -- Researchers claim to have found a way to better customize the treatment of prostate cancer.

Four risk factors that can help predict how long men could survive with metastatic prostate cancer have been identified by researchers from the Duke Comprehensive Cancer Center, who say such information would help doctors individualize treatments.

"There is a need for identification of accurate and simple-to-use prognostic factors for men with prostate cancer that has spread beyond the prostate," Andrew Armstrong, a medical oncologist at Duke and the lead investigator for the study, said in a university news release. "Our study was aimed at developing accurate predictors which may be used to assist in clinical decision making and also in planning clinical trials for men whose disease has stopped responding to hormone therapy."

By studying the records of more than 1,000 men who were taking part in a study of the chemotherapeutic drug docetaxel and its effect on metastatic prostate cancer, the researchers found four risk factors that predicted how well someone would respond to treatment:

  • The presence of cancer-related pain
  • Anemia
  • How extensively the cancer has spread to other organs
  • The progression of cancer in bone

"Using these predictors, we were able to assign patients to risk groups of good -- indicating an average survival of about two years; intermediate -- with survival of about 1.5 years; and poor -- with survival of less than a year," Armstrong said.

"By knowing a patient's prognosis and expected responses to chemotherapy, we are better able to discuss and determine whether a more- or less-aggressive treatment plan might be advisable," he said.

Another benefit is long-range knowledge, Armstrong said. Identifying men's prognoses and how they are expected to respond to treatment also would help determine whether a drug is ready for a phase 2 trial, which test a treatment that has been shown to help some people. It usually compares a newer treatment to the gold standard, or best-known treatment.

"We're eager to use this information to accurately estimate what to expect with current therapies," Armstrong said.

The findings are to be made available to those attending the American Society of Clinical Oncology's annual meeting in Orlando, Fla., in late May.

More information

The American Cancer Society has more about prostate cancer.



-- Dennis Thompson



SOURCE: Duke University, news release, May 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tailoring glioblastoma therapies: 1 size does not fit all
2. The Childrens Hospital of Philadelphia Receives Grant to Study Tailoring Pediatric Preventive Care to Individual Needs
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. First biomarker discovered that predicts prostate cancer outcome
5. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
6. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
7. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
8. Red wine compound shown to prevent prostate cancer
9. Barbershop Talks Cut Black Mens Prostate Cancer Risk
10. Generic prostate drug helps find high-risk cancers early
11. Finasteride unlikely to induce high grade prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
An Aid to Tailoring Prostate Cancer Treatment
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... SHANGHAI, China – , ... ... public health organization NSF International has certified the first drinking ... 53: Drinking Water Treatment Units – Health Effects, an American ... that MicroCeramics’ NanoNose Pitcher Filter System filters the water to ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor ... Smile Train, an international charity that provides free surgery to poor children suffering from ... in the past I have run to support the efforts of the American Heart ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... offering asset protection and financial planning services to families and business owners in ... event aimed at supporting children with developmental disabilities. , The Lakemary Center is ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that Mr. Michael Merges, Director of Strategic Growth, ... be held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 18, 2017 ML Capital ... to publish an online presentation tomorrow, January 19 ... forecast for 2017. Management reports that the forecast ... sales performance from its existing operations, and the ... into the Cannabis sector through a partnership ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology: